SPL Medical receives approval for Clinical Trial with contrast agent Ferrotran® in 10 top radiology centers.

15 März SPL Medical receives approval for Clinical Trial with contrast agent Ferrotran® in 10 top radiology centers.

SPL Medical BV has received approval of the German regulatory body for pharmaceutical products BfArM, to the start of a multicenter clinical trial of Ferrotran^®. This is a novel contrast agent (based on Ferumoxtran-10) for use in MRI (magnetic resonance imaging), developed for the (early) detection of lymph node metastases of prostate cancer. Ferrotran^® is the only contrast agent that can detect lymph node metastases as small as 2 mm. Standard MRI or CT are normally not able to detect nodes smaller than 7-8 mm.